The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly
to HTML. Please use the page image as the authoritative form to
ensure accuracy. this estimate does not include costs associated
with newly described STD-related syndromes such as premature
delivery in pregnant women and low birth weight associated with
bacterial vaginosis. Comprehensive and accurate data regarding
the economic costs of STDs are essential for cost-effectiveness
analyses of prevention programs, but cost and morbidity data are
not currently available for many STDs and related syndromes.
Therefore, the CDC or other appropriate federal agency should
conduct or support a comprehensive analysis of the economic
consequences of STDs and associated sequelae. This analysis
should include estimates of direct and indirect costs and
appropriate cost-benefit and cost-effectiveness analyses of
interventions. The current national response to STDs is not
commensurate with their health and eco